Can I read Conjugation of Cetuximab – Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines on EtoBox?

Conjugation of Cetuximab – Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines by Diah Puspitasari; Septelia Wanandi; Mohamad Sadikin is a Medicine article available to read on EtoBox.

What is Conjugation of Cetuximab – Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines about?

Cancer is life-threatening disease and being global health problems. Chemotherapy is one of the most used therapy for cancer since many years ago. Chemotherapy is also toxic for normal cell, not specific to the target cells. Consequently, chemotherapy has various side effects. Monoclonal antibody (MAb) has been developed for specific therapy which only has killing effect in cancer cells, but the survival rate of most MAbs around 20%. Therefore, in clinical practice, MAbs administration should combine with chemotherapeutic agents. For effectiveness of therapy and to minimalize adverse effects, anticancer agent with selective cytotoxic effect on target cells is needed, the immunotoxin. ## Objective: This study introduces a novel approach to conjugate monoclonal antibody (Cetuximab) and toxin (Puromycin), in order to selectively inhibit proliferation of triple negative breast cancer (TNBC) and to enhance the efficacy of MAb in target cells killing. ## Methods: Cetuximab was conjugated with Puromycin using a linker, i.e SATP (Succinimidyl-acetylthiopropionate) and tested on triple negative breast cancer cell lines (MDA-MB-231) which expressed EGFR (epidermal growth factor receptor). Ce

Who reads Conjugation of Cetuximab – Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines?

Author

Diah Puspitasari; Septelia Wanandi; Mohamad Sadikin

Publisher

EpiSmart Science Vector Ltd

Published

2022

Language

EN

Field

Medicine (Health Sciences)